# A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

> **NCT05063539** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 327 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** LY3372689
- **DRUG:** LY3372689
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05063539
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-16
- **Primary completion:** 2024-07-09
- **Final completion:** 2025-05-22
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05063539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05063539, "A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT05063539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*